期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 70, 期 5, 页码 607-619出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2017.05.057
关键词
drug-eluting stent; dual antiplatelet therapy; high bleeding risk patients; in-stent restenosis; stent thrombogenicity; stent thrombosis
The introduction of bare-metal stents (BMS) has represented a major advancement over plain old balloon angioplasty in the management of coronary artery disease. However, the high rates of target lesion revascularization associated with use of BMS have led to the development of drug-eluting stents, which require prolonged dual antiplatelet therapy due to the increased risk of late and very late stent thrombosis. The improvements in newer-generation drug-eluting stents have translated into better safety and efficacy compared with earlier generation and BMS, thus allowing shorter dual antiplatelet therapy duration. Here, we aim to provide reasons as to why we still need BMS in our cardiac catheterization laboratory. (C) 2017 by the American College of Cardiology Foundation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据